Oruka Therapeutics Valuation
Is HQ1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HQ1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HQ1's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HQ1's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HQ1?
Key metric: As HQ1 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is HQ1's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | €0 |
| Market Cap | €619.13m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does HQ1's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.9x | ||
FYB Formycon | 1.5x | 31.5% | €857.2m |
BIO3 Biotest | 2x | 29.3% | €1.3b |
HPHA Heidelberg Pharma | 3x | -33.0% | €105.8m |
2INV 2invest | 1x | n/a | €62.7m |
HQ1 Oruka Therapeutics | n/a | n/a | €654.1m |
Price-To-Book vs Peers: Insufficient data to calculate HQ1's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does HQ1's PB Ratio compare vs other companies in the DE Biotechs Industry?
| 3 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: Insufficient data to calculate HQ1's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is HQ1's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate HQ1's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €17.70 | €41.13 +132.4% | 7.5% | €46.69 | €38.11 | n/a | 6 |
| Nov ’25 | €25.20 | €39.69 +57.5% | 7.5% | €45.05 | €36.78 | n/a | 6 |
| Oct ’25 | €21.60 | €36.91 +70.9% | 4.0% | €39.37 | €35.79 | n/a | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.8b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$15.65
7D
-3.7%
1Y
76.2%
Collegium Pharmaceutical
US$1.0b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.60
7D
5.7%
1Y
27.6%
Pharming Group
€491.5m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.70
7D
-0.7%
1Y
-34.1%